European Urology
Volume 50, Issue 2 , Pages 317-326 , August 2006

Differential Effects of the Antimuscarinic Agents Darifenacin and Oxybutynin ER on Memory in Older Subjects

  • Gary Kay

      Affiliations

    • Washington Neuropsychological Institute, Washington, DC, USA
    • Corresponding Author InformationCorresponding author. Washington Neuropsychological Institute, 4910 Massachusetts Ave NW #100, Washington, DC 20016, USA. Tel. +1 202 686 7520; Fax: +1 202 686 8802.
    • ,
  • Thomas Crook

      Affiliations

    • Psychologix, Inc, Fort Lauderdale, FL, USA
    • ,
  • Ludmyla Rekeda

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • Raul Lima

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • Ursula Ebinger

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    • ,
  • Miguel Arguinzoniz

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Michael Steel

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland

,Accepted 13 March 2006.

References 

  1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766
  2. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3 receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2001;21:243–248
  3. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786–799
  4. Crook TH, Lebowitz D, Pirozzolo FJ, et al. Recalling names after introduction: changes across the adult life span in two cultures. Development Neuropsychol. 1993;9:103–113
  5. Norbury R, Travis MJ, Erlandsson K, et al. SPET imaging of central muscarinic receptors with (R,R) [123I]–I–QNB: methodological considerations. Nucl Med Biol. 2004;31:583–590
  6. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose response study. Arch Gen Psychiatry. 1987;44:418–426
  7. Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology. 1992;107:437–441
  8. Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev. 1992;17:215–226
  9. Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol Urodyn. 2002;21:A445
  10. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6:51–58
  11. Drachman DA, Noffsinger D, Sahakian BJ, Kurdziel S, Fleming P. Aging, memory, and the cholinergic system: A study of dichotic listening. Neurobiol Aging. 1980;1:39–43
  12. Andersson K-E. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl. 2002;1(4):23–28
  13. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 2005;96:1055–1062
  14. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173:493–498
  15. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D’Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8–13
  16. Ditropan XL® (oxybutynin chloride) Extended Release Tablets. Prescribing Information. Ortho-McNeil Pharmaceutical, Inc., June 2004 (available at: http://www.ditropanxl.com/professional/full_presc.htm).
  17. Enablex® (darifenacin) Extended Release Tablets. Prescribing Information. Novartis Pharmaceuticals Corporation, December 2004 (available at: http://www.pharma.us.novartis.com/product/pi/pdf/enablex.pdf).
  18. Crook TH, Larrabee GJ. A self-rating scale for evaluating memory in everyday life. Psychol Aging. 1990;5:48–57
  19. Youngjohn JR, Larrabee GJ, Crook TH. First-last Names and Grocery List Selective Reminding Test: two computerized measures of everyday verbal learning. Arch Clin Neuropsychol. 1991;6:287–300
  20. Crook TH, West RL. Name recall performance across the adult life-span. Br J Psychol. 1990;81(Pt. 3):335–349
  21. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology. 1999;24:115–128
  22. Crook TH, Youngjohn JR, Larrabee GJ, Salama M. Aging and everyday memory: a cross-cultural study. Neuropsychol. 1992;6:123–136
  23. Crook TH, Youngjohn JR, Larrabee GJ. The misplaced objects test: a measure of everyday visual memory. J Clin Exp Neuropsychol. 1990;12:819–833
  24. Coffey DJ, Jenkyn LR, Coffey AK, Wells BB. Sertraline vs amitriptyline vs placebo: effects on cognitive and motor functioning in the elderly. Neuropsychopharmacology. 1994;10(Suppl 2):222S
  25. Skerjanec A, Devineni D. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45:325–350
  26. Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res. 2004;145:59–66
  27. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95:993–1001
  28. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three Phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48:471–477
  29. Power AE, Vazdarjanova A, McGaugh JL. Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem. 2003;80:178–193
  30. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005;27:144–153

PII: S0302-2838(06)00358-7

doi: 10.1016/j.eururo.2006.03.057

European Urology
Volume 50, Issue 2 , Pages 317-326 , August 2006

Article Tools

* Image Usage & Resolution